华兰生物
(002007)
| 流通市值：260.45亿 | | | 总市值：302.44亿 |
| 流通股本：15.74亿 | | | 总股本：18.27亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,160,346,064.35 | 1,102,190,831.95 | 1,366,659,508.49 | 843,155,746.52 |
| 交易性金融资产 | 1,767,147,237.15 | 2,546,993,797.38 | 1,888,018,536.66 | 1,778,362,117.82 |
| 应收票据及应收账款 | 1,581,262,799.13 | 1,870,813,379.2 | 1,798,428,848.41 | 2,368,410,452.42 |
| 应收账款 | 1,581,262,799.13 | 1,870,813,379.2 | 1,798,428,848.41 | 2,368,410,452.42 |
| 应收款项融资 | 145,854,393.56 | 197,154,765.85 | 253,783,518.89 | 145,781,458.71 |
| 预付款项 | 45,443,452.17 | 91,106,230.94 | 71,954,565.75 | 68,099,249.18 |
| 其他应收款合计 | 15,072,120.24 | 19,375,503.95 | 18,322,717.98 | 16,568,395.25 |
| 存货 | 2,303,490,511.79 | 2,231,831,545.8 | 2,028,565,707.69 | 1,905,908,043.12 |
| 一年内到期的非流动资产 | 2,261,027,215.27 | 2,384,265,798.6 | 2,143,615,395.82 | 2,049,849,472.23 |
| 其他流动资产 | 56,420,440.24 | 106,091,894.22 | 46,842,268.5 | 90,094,251.37 |
| 流动资产合计 | 9,336,064,233.9 | 10,549,823,747.89 | 9,616,191,068.19 | 9,266,229,186.62 |
| 非流动资产: | | | | |
| 长期股权投资 | - | - | - | 6,034,995.1 |
| 固定资产 | 2,382,511,896.99 | 2,404,631,459.2 | 2,401,604,027.3 | 2,039,752,564.37 |
| 在建工程 | 584,891,844.39 | 563,982,791.49 | 552,479,848.58 | 792,268,823.88 |
| 生产性生物资产 | 523,090.71 | 531,685.26 | 929,509.83 | 856,329.92 |
| 使用权资产 | 8,832,676.59 | 8,975,971.83 | 9,119,267.07 | 9,262,562.33 |
| 无形资产 | 313,548,524.8 | 316,138,918.75 | 319,041,041.19 | 315,925,342.79 |
| 开发支出 | 27,864,900.22 | 27,864,900.22 | 27,791,873.06 | 27,635,945.37 |
| 长期待摊费用 | 28,949,829.45 | 30,408,318.72 | 31,896,416.89 | 29,998,078.97 |
| 递延所得税资产 | 243,947,882.17 | 224,119,716.13 | 235,338,950.16 | 207,864,992.45 |
| 其他非流动资产 | 2,608,305,521.29 | 2,512,443,441.86 | 3,115,559,353.02 | 3,405,777,581.38 |
| 非流动资产合计 | 6,199,376,166.61 | 6,089,097,203.46 | 6,693,760,287.1 | 6,835,377,216.56 |
| 资产总计 | 15,535,440,400.51 | 16,638,920,951.35 | 16,309,951,355.29 | 16,101,606,403.18 |
| 流动负债: | | | | |
| 短期借款 | 280,000,000 | 1,079,380,000 | 899,730,000 | 600,000,000 |
| 应付票据及应付账款 | 206,262,397.24 | 230,809,400.13 | 217,162,847.72 | 204,658,855.82 |
| 其中：应付票据 | 12,005,502.08 | - | - | 6,907,330 |
| 应付账款 | 194,256,895.16 | 230,809,400.13 | 217,162,847.72 | 197,751,525.82 |
| 合同负债 | 21,687,891.8 | 16,962,615.42 | 13,461,361.08 | 9,792,652.49 |
| 应付职工薪酬 | 112,608.82 | 477,374.46 | 79,569.2 | 514,696.99 |
| 应交税费 | 36,515,630.06 | 43,023,308.74 | 33,559,564.57 | 72,187,599.07 |
| 其他应付款合计 | 920,293,938.12 | 931,285,577.35 | 1,122,852,834.18 | 1,252,431,049.07 |
| 应付股利 | 116,366,935.6 | - | 93,931,367.58 | 93,323,867.58 |
| 一年内到期的非流动负债 | 371,353.82 | 371,353.82 | 371,353.82 | 150,761,507.75 |
| 其他流动负债 | 648,434.2 | 66,066,116.37 | 72,904,525 | 293,699.54 |
| 流动负债合计 | 1,465,892,254.06 | 2,368,375,746.29 | 2,360,122,055.57 | 2,290,640,060.73 |
| 非流动负债: | | | | |
| 租赁负债 | 8,214,514.84 | 8,114,955.67 | 8,776,904.26 | 8,671,814.23 |
| 递延收益 | 50,820,903.74 | 52,501,438.87 | 54,181,974 | 46,457,509.13 |
| 递延所得税负债 | 40,208,851.19 | 37,359,105.56 | 40,144,438.04 | 44,740,117.74 |
| 非流动负债合计 | 99,244,269.77 | 97,975,500.1 | 103,103,316.3 | 99,869,441.1 |
| 负债合计 | 1,565,136,523.83 | 2,466,351,246.39 | 2,463,225,371.87 | 2,390,509,501.83 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 1,827,456,666 | 1,828,780,926 | 1,828,780,926 | 1,828,780,926 |
| 资本公积 | 1,420,562,053.53 | 1,430,209,795.99 | 1,429,993,625.13 | 1,446,836,942.14 |
| 减:库存股 | 17,948,737.2 | 32,723,064.6 | 32,723,064.6 | 46,746,378 |
| 盈余公积 | 897,821,103.29 | 897,821,103.29 | 897,821,103.29 | 806,811,676.78 |
| 未分配利润 | 7,885,280,035.22 | 8,048,047,860.37 | 7,734,911,875.63 | 7,661,329,272.72 |
| 归属于母公司股东权益合计 | 12,013,171,120.84 | 12,172,136,621.05 | 11,858,784,465.45 | 11,697,012,439.64 |
| 少数股东权益 | 1,957,132,755.84 | 2,000,433,083.91 | 1,987,941,517.97 | 2,014,084,461.71 |
| 股东权益合计 | 13,970,303,876.68 | 14,172,569,704.96 | 13,846,725,983.42 | 13,711,096,901.35 |
| 负债和股东权益合计 | 15,535,440,400.51 | 16,638,920,951.35 | 16,309,951,355.29 | 16,101,606,403.18 |
| 公告日期 | 2025-08-28 | 2025-04-28 | 2025-03-29 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |